PCAS key Figures (2017)

€218.3

million


Consolidated net sales

7


Production sites

€31.5

million


EBITDA
Earnings before interest, taxes, depreciation and amortization

1071


Employees

PCAS sales
/ by geographic zone /

diagram-1-2018
  • 40%
    Europe
  • 28%
    France
  • 15%
    Asian Pacific
  • 14%
    North America
  • 3%
    Others

PCAS sales
/ by market /

diagram-2-2018
  • 46%
    Pharma Synthesis Exclusive & Pharma Chemicals
  • 22%
    Pharma Sythesis Generic APls
  • 16%
    Performance Fine Chemicals
  • 16%
    Advanced Specialties

Breakdown of PCAS
Share Capital at
12/31/2017

diagram-3-2018
  • 76.14%
    Novacap
  • 7.79%
    Public
  • 7.66%
    Auto detention
  • 6.58%
    Inocap gestion*
  • 1.83%
    Management
In millions of euros20162017
Net sales192.0218.3
Pharmaceutical synthesis
Fine specialty chemicals
130.0
62.0
148.9
69.3
EBITDA*27.331.5
EBITDA margin14.2%14.4%
EBIT*16.219.1
EBIT margin8.4%8.8%
Other operating income and expenses
Financial result
Taxes
-2.3
-6.4
-0.9
-5.2
-4.4
-3.8
Net Income6.65.8
Equity
Net debt
97.0
48.7
103.5
56.7
Gearing0.500.55
Net asset attributable to the Group per share6.857.26

*Including research tax credit of €3.3 million in 2016 and €3.7 million 2017.

key figures

At February 20 2018

Code ISINFR 0000053514 - PCA
Number of actions15 141 725
Excluding self-detention13 981 675
CompartmentEuronext C Market
Share price18.74 euros
Market capitalization283.8 millions euros
Analyst coverageKepler Chevreux - Portzamparc and Midcap Partners

PCAS and the stock market

Key adjusted per share figures

In euros20162017
Highest price14.0618.81
Lowest price6.7512.11
Price at the end of December14.0218.12
Net sales12.6814.41
Current operating income1.071.26
Net profit attributable to the Group0.450.41

PCAS shares are listed on Nyse Euronext, compartment C. The shares have been continuously listed since October 17, 1996 and are subject to a liquidity contract with Kepler Cheuvreux.

PCAS 2017 share price


diagramme-courbe-2018

Contacts: